Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Neurizon Sets Out Funding Plan Ahead Of ALS Trial Results

NUZ: $0.062 -4.62% · MC: $48M

Neurizon’s investor presentation recaps its $4.3 million placement and proposed $2 million share purchase plan, alongside redemption of all remaining Obsidian convertible notes. The company says the funding is intended to strengthen its position ahead of anticipated HEALEY ALS Platform Trial results in late Q2 2027; the webinar is scheduled for today.

Source announcements: 2026-11-05 09:58 to 2026-11-05 09:58 Sydney time
Story updated 2026-11-05 10:05 Sydney time
SourcesInvestor webinar reminder and presentation
Comments